Guardant Health Surges 6M in Pre-Market Trading After Impressive Fiscal Year 2022 Results
January 10, 2023
Trending News ☀️
Guardant Health ($NASDAQ:GH) is a leading precision oncology company that helps diagnose and treat cancer. Guardant Health’s products enable earlier detection of cancer, leading to more effective treatments and improved outcomes. The company’s technology platform helps to rapidly identify tumor DNA and create more accurate, personalized cancer diagnostics and treatments. Guardant Health’s fiscal year 2022 and fourth quarter results were particularly impressive, with pre-market trading seeing the company surge 6. 24%. The company expects revenue to be between $447 million and $450 million, a 20% Y/Y increase, compared to their prior projection of $440 million to $450 million, and better than the estimated figure of $445. 6 million. Furthermore, the company reported wider margins and a strong order book, further cementing their position as a leader in precision oncology. This test has allowed for more accurate diagnosis of cancer, resulting in more effective treatment options.
In addition, Guardant Health’s other products are also seeing strong demand, such as their LUNAR platform which enables the real-time monitoring of cancer progression. 24%. These results demonstrate the success of the company’s innovative technology and products, and sets them up for continued growth and success in the future.
Market Price
The media exposure surrounding the company has been largely positive, and the stock opened at $28.0 before closing at $27.8, representing a 7.1% increase from the previous closing price of $26.0. The surge in pre-market trading has continued to be a positive indicator for Guardant Health and its investors. It is indicative of a strong outlook for the company, especially considering the impressive fiscal year 2022 results it has reported. This strong performance is expected to continue in the coming months, and investors are confident that Guardant Health’s stock will continue to rise.
Additionally, Guardant Health’s products have been receiving positive reviews from customers, which is helping to boost its stock price. Its products are designed to make cancer detection more accurate and efficient, with its sequencing technology providing a comprehensive analysis of a person’s DNA to identify any potential genetic mutations. This technology has seen a surge in popularity among medical professionals, and the company is now looking to expand its product line even further. Overall, the pre-market trading surge for Guardant Health indicates that investors are confident in the company’s future prospects. Its impressive fiscal year 2022 results show that it is well on track to reach its goals, and its products are also receiving positive reviews from customers. With this in mind, it seems as though Guardant Health’s stock price is set to continue to rise in the coming months. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Guardant Health. More…
| Total Revenues | Net Income | Net Margin |
| 430.75 | -605.57 | -108.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Guardant Health. More…
| Operations | Investing | Financing |
| -295.7 | -187.51 | -187.63 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Guardant Health. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.7k | 1.54k | 1.63 |
Key Ratios Snapshot
Some of the financial key ratios for Guardant Health are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 32.7% | – | -102.2% |
| FCF Margin | ROE | ROA |
| -90.0% | -150.2% | -21.4% |
VI Analysis
Investing in a company can be a difficult process, especially when it comes to evaluating its long-term potential. Fortunately, there are tools available to help simplify this process, such as the VI App. By using this app to evaluate Guardant Health, we can determine that it is a medium risk investment, based on its financial and business aspects. The VI App has identified three risk warnings in the company’s balance sheet, cashflow statement, and non-financial areas. These warnings are important to consider when deciding whether or not to invest in the company. It is also important to note that when evaluating any company, the fundamentals should always be taken into account. In addition to using the VI App, investors should also do their own research, including examining the company’s financial statements, current economic conditions, and industry trends. This can help investors make more informed decisions and better understand the company’s long-term potential. To ensure that all necessary information is taken into account, investors should also consult with a financial adviser who has experience with investing in the company. Overall, Guardant Health is classified as a medium risk investment based on its financial and business aspects. However, investors should always take the time to do their own due diligence before committing to an investment in any company. By taking the time to do the necessary research and consulting with a financial adviser, investors can better understand the company’s long-term potential and make more informed decisions when it comes to investing. More…
VI Peers
The competition in the market for cancer detection and treatment is heating up. Guardant Health Inc, a leading player in the field, is up against some stiff competition from the likes of Aclaris Therapeutics Inc, Inoviq Ltd, and Biomark Diagnostics Inc. All these companies are vying for a share of the pie in this rapidly growing market. While Guardant Health Inc has a strong product portfolio and a good track record, its competitors are not far behind and are also making inroads into this market. It remains to be seen who will emerge victorious in this battle.
– Aclaris Therapeutics Inc ($NASDAQ:ACRS)
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of drugs for the treatment of dermatological and immuno-inflammatory diseases. The company’s lead product candidates include ATI-502 for the treatment of seborrheic keratosis, and ATI-501 for the treatment of vitiligo. Aclaris Therapeutics Inc has a market cap of 1.11B as of 2022, a Return on Equity of -25.42%.
– Inoviq Ltd ($ASX:IIQ)
Inoviq Ltd is a publicly traded company with a market capitalization of 50.61M as of 2022. The company’s return on equity (ROE) is -13.68%. Inoviq Ltd is engaged in the development and commercialization of innovative drugs and therapies. The company’s products are designed to improve the lives of patients with serious medical conditions. Inoviq’s products are available in more than 60 countries worldwide.
– Biomark Diagnostics Inc ($OTCPK:BMKDF)
Biomark Diagnostics Inc is a company that provides diagnostic testing services. The company has a market capitalization of 10.88 million as of 2022 and a return on equity of 179.57%. The company’s diagnostic testing services include tests for cancer, cardiovascular disease, and infectious diseases. Biomark Diagnostics Inc is headquartered in the United States.
Summary
Guardant Health‘s stock has seen impressive gains in pre-market trading following its positive financial results for the fiscal year 2022. The company has been met with mostly positive media coverage, which has contributed to its stock price appreciation. With product innovation and solid financial performance, Guardant Health is a promising investment opportunity for those looking to diversify their portfolios in the healthcare sector.
Their technology provides genomic testing solutions that facilitate early disease detection, enabling patients to receive personalized treatment. Investors should consider the company’s long-term fundamentals and potential for growth before making any decisions.
Related Posts
Recent Posts
